ClinicalTrials.gg
RecruitingNCT06482463TOTEMUpdated Dec 31, 2025

Diagnostic of D-lactate in Cerebrospinal Fluid Level in Patients With Suspected Ventriculostomy-related Meningitis

An interventional study of CSF sample in Nosocomial Infection, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
185
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Cross Infection with a site in France — 8 open to participants now, 9 under way, 1 of them phase 3. Cross Infection · France.

Planned enrollment
14th of 23
185 · median 244
Started
2025
with 1 other
No phase
14 of 47
3 open now
Registered
41st of 47
by date

Among the 47 studies in Cross Infection with a site in France, this one is the 14th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 with no phase, and was the 41st registered.

Cross Infection

287 studies on the registry are indexed under Cross Infection; 47 are open to participants now.

Browse Cross Infection studies →

Open to participants now

8 of the 47 studies in Cross Infection with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 27 Cross Infection studies recruiting now, 23 (85%) set no upper age limit and 2 (7%) stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Cross Infection with a site in France, or all of them as a file.
02

Study summary

The TOTEM study is a single-center study designed to evaluate the performance of the D-lactate assay in cerebrospinal fluid (CSF) for the diagnosis of ventriculostomy-related nosocomial meningitis. The study will be conducted in the neurosurgical intensive care unit of the Toulouse University Hospital, in patients with a suspected diagnosis of ventriculostomy-related nosocomial meningitis.

Read the detailed description

For each study participant, an additional CSF sample will be taken from the ventriculostomy during the routine sampling performed for the diagnosis of nosocomial meningitis. This sample will be stored at -80°C. Assays of D-lactate, procalcitonin (PCT), and pro-inflammatory cytokines (IL-1, IL-6, IL-8, TNFa) will be performed serially on these CSF samples.

If the CSF sample taken at inclusion does not meet the criteria for nosocomial meningitis, a second sample will be taken 48 to 96 hours later to reassess the cellularity of the CSF. Finally, the end-of-participation visit takes place after 4 weeks. Two neurosurgical reanimators will retrospectively diagnose nosocomial meningitis, or the absence of meningitis, according to the information from the patient's medical records.

03

Conditions studied

  • Nosocomial Infection

Keywords

  • External ventriculostomy
  • Nosocomial meningitis
  • Bacterial meningitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ⩾ 18 years.
  • Patient with an external ventriculostomy implanted at the Toulouse University Hospital.
  • Patient suspected of nosocomial meningitis due to a febrile syndrome (in the absence of any other identified infectious site), headache, nausea, lethargy, change in neurological status, meningeal syndrome, epileptic event and cutaneous or subcutaneous inflammation at the ventriculostomy site of insertion.
  • Patient having expressed oral consent, after free and informed information.
  • Patient affiliated to a social security scheme.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of community meningitis.
  • Proven or suspected meningitis and/or ventriculitis during the previous month.
  • Diagnosis of nosocomial meningitis made in another medical centre prior to admission.
  • Short bowel syndrome.
  • Acute mesenteric ischaemia.
  • End-stage renal failure ( \< 15 ml/min/m2).
  • Peritoneal dialysis.
  • Patient participating in another research protocol with an exclusion period still in progress.
  • Pregnant or breastfeeding woman.
  • Patient under guardianship or trusteeship, persons placed under the protection of justice
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
185 participants (estimated)

Study arms

  • Experimental
    Ventriculostomy-related nosocomial meningitis

    Finally, two neurosurgical reanimators will retrospectively diagnose nosocomial meningitis, or the absence of meningitis, according to the information from the patient's medical records.

    Biological: CSF sample

  • Other
    Absence of nosocomial meningitis

    Finally, two neurosurgical reanimators will retrospectively diagnose nosocomial meningitis, or the absence of meningitis, according to the information from the patient's medical records.

    Biological: CSF sample

Interventions

  • BiologicalCSF sample

    an additional CSF sample of 1 ml is taken from the external ventriculostomy

06

What researchers measure

Primary outcomes

  1. Comparison of Sensitivity of CSF D-Lactate for Ventriculostomy-Related Nosocomial Meningitis

    Calculation of the sensitivity obtained for the determination of CSF D-lactate in patients with suspected ventriculostomy-related nosocomial meningitis. Thes parameter will be compared with those obtained for the usual biological markers.

    Time frame: Day 0

  2. Comparison of Specificity of CSF D-Lactate for Ventriculostomy-Related Nosocomial Meningitis

    Calculation of the specificity obtained for the determination of CSF D-lactate in patients with suspected ventriculostomy-related nosocomial meningitis. Thes parameter will be compared with those obtained for the usual biological markers.

    Time frame: Day 0

Secondary outcomes

  1. sensitivity Parameter of Combined D-Lactate and Pro-Inflammatory Cytokines in CSF

    sensitivity parameter calculated for the combined assay of D-lactate and pro-inflammatory cytokines in CSF.

    Time frame: Day 0

  2. specificity Parameter of Combined D-Lactate and Pro-Inflammatory Cytokines in CSF

    specificity parameter calculated for the combined assay of D-lactate and pro-inflammatory cytokines in CSF.

    Time frame: Day 0

  3. Sensitivity Parameter of Combined D-Lactate and and cyto-biochemical parameters in CSF.

    sensitivity parameter calculated for the combined assay of D-lactate and routinely assayed cyto-biochemical parameters (L-lactate, proteins, glucose, cellularity) in CSF.

    Time frame: Day 0

  4. specificity Parameter of D-lactate and cyto-biochemical parameters in CSF.

    specificity parameter calculated for the combined assay of D-lactate and routinely assayed cyto-biochemical parameters (L-lactate, proteins, glucose, cellularity) in CSF.

    Time frame: Day 0

  5. Sensitivity Parameter of D-lactate in CSF depending on the nature of the bacterial species identified.

    Sensitivity Parameter calculated for the D-lactate assay in CSF according to the nature of the bacterial species identified.

    Time frame: Day 0

  6. specificity Parameter of D-lactate in CSF depending on the nature of the bacterial species identified.

    specificity Parameter calculated for the D-lactate assay in CSF according to the nature of the bacterial species identified.

    Time frame: Day 0

  7. Sensitivity Parameter of D-lactate in CSF according to the presence or absence of antibiotic therapy before collection.

    Sensitivity Parameter calculated for the determination of D-lactate in CSF according to the presence or absence of antibiotic therapy prior to sampling.

    Time frame: Day 0

  8. specificity Parameter of D-lactate in CSF according to the presence or absence of antibiotic therapy before collection.

    specificity Parameter calculated for the determination of D-lactate in CSF according to the presence or absence of antibiotic therapy prior to sampling.

    Time frame: Day 0

  9. Sensitivity Parameter for the determination of CSF D-lactate in culture-negative bacterial meningitis.

    Densitivity Parameter calculated for the determination of D-lactate in CSF in culture-negative bacterial meningitis.

    Time frame: Day 0

  10. specificity Parameter for the determination of CSF D-lactate in culture-negative bacterial meningitis.

    specificity Parameter calculated for the determination of D-lactate in CSF in culture-negative bacterial meningitis.

    Time frame: Day 0

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.

Of 59 non-industry interventional studies with no phase under Cross Infection, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 24 months is above that.

Counting every sponsor, half of 61 studies reached it within 16 months; a quarter within 7 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2024
First posted
Jul 1, 2024
StartActual
Feb 12, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06482463
Responsible party
Sponsor
First posted
Jul 1, 2024
Start date
Feb 12, 2025
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Dec 31, 2025

Study contacts

Lucie LELIEVRE, Md
Contact
lelievre.l@chu-toulouse.fr
0561777198 ext. +33
Guillaume MARTIN-BLONDEL, Md
Contact
martin-blondel.g@chu-toulouse.fr
0561779699 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion